| Medical and Health Sciences | 2021-2025 | 53 | IT 2 | 99.99 |
| Oncology | Lifetime | 706 | IT 26 | 98.57 |
| Hepatology | Lifetime | 630 | IT 48 | 90.60 |
| Surgery | 2021-2025 | 15 | IT 4 | 99.91 |
| Oncology | 2021-2025 | 13 | IT 1 | 99.92 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 49 | IT 2 | 99.75 |
| Hepatology | 2021-2025 | 93 | IT 7 | 96.72 |
| Cancer Research | 2021-2025 | 214 | IT 4 | 88.18 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 287 | IT 9 | 99.30 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 175 | IT 10 | 99.07 |
| Peptidase Inhibition and Analysis | Lifetime | 568 | IT 24 | 98.04 |
| Ferroptosis and cancer prognosis | Lifetime | 290 | IT 3 | 96.57 |
| Gallbladder and Bile Duct Disorders | Lifetime | 467 | IT 34 | 98.06 |
| Cancer Mechanisms and Therapy | Lifetime | 232 | IT 13 | 97.55 |
| Hepatocellular Carcinoma Treatment and Prognosis | Lifetime | 671 | IT 66 | 98.02 |
| Renal cell carcinoma treatment | Lifetime | 605 | IT 52 | 97.58 |
| Fibroblast Growth Factor Research | Lifetime | 687 | IT 23 | 92.22 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 4 | IT 1 | 99.97 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 6 | IT 1 | 99.80 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 16 | IT 5 | 99.65 |
| Cancer Mechanisms and Therapy | 2021-2025 | 7 | IT 1 | 99.09 |
| Renal cell carcinoma treatment | 2021-2025 | 25 | IT 6 | 99.42 |
| Hepatocellular Carcinoma Treatment and Prognosis | 2021-2025 | 50 | IT 6 | 99.19 |
| Gallbladder and Bile Duct Disorders | 2021-2025 | 39 | IT 16 | 98.87 |
| Peptidase Inhibition and Analysis | 2021-2025 | 43 | IT 2 | 99.01 |
| Ferroptosis and cancer prognosis | 2021-2025 | 75 | IT 1 | 98.42 |
| Bladder and Urothelial Cancer Treatments | 2021-2025 | 62 | IT 10 | 99.01 |
| Fibroblast Growth Factor Research | 2021-2025 | 14 | IT 2 | 98.01 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 393 | IT 26 | 97.42 |
| Urinary and Genital Oncology Studies | 2021-2025 | 128 | IT 17 | 96.95 |
| Pediatric Hepatobiliary Diseases and Treatments | 2021-2025 | 153 | IT 24 | 94.11 |
| HER2/EGFR in Cancer Research | 2021-2025 | 286 | IT 25 | 95.44 |
| Gastrointestinal Tumor Research and Treatment | 2021-2025 | 308 | IT 20 | 92.21 |
| Renal and related cancers | 2021-2025 | 377 | IT 47 | 90.03 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 876 | IT 102 | 90.07 |
| Breast Cancer Treatment Studies | 2021-2025 | 926 | IT 81 | 90.55 |
| Cancer Treatment and Pharmacology | 2021-2025 | 795 | IT 56 | 86.15 |
| Advanced Breast Cancer Therapies | 2021-2025 | 894 | IT 86 | 84.45 |
| Viral-associated cancers and disorders | 2021-2025 | 952 | IT 53 | 77.27 |
